Neoadjuvant Nivolumab, Ipilimumab Safe for dMMR Colon Cancer
By Elana Gotkine HealthDay Reporter
WEDNESDAY, June 5, 2024 -- Neoadjuvant nivolumab plus ipilimumab has an acceptable safety profile in patients with locally advanced mismatch repair-deficient (dMMR) colon cancer, according to a study published in the June 6 issue of the New England Journal of Medicine.
Myriam Chalabi, M.D., Ph.D., from the Netherlands Cancer Institute in Amsterdam, and colleagues conducted a phase 2 study involving patients with nonmetastatic, locally advanced, previously untreated dMMR colon cancer treated with neoadjuvant nivolumab plus ipilimumab. Safety, defined by timely surgery, and three-year disease-free survival were the two primary end points.
The researchers found that 113 of the 115 enrolled patients underwent timely surgery; two had surgery delayed by more than two weeks. In five patients (4 percent), grade 3 or 4 immune-related adverse events occurred; no patients discontinued treatment due to adverse events. A pathological response occurred in 98 percent of the 111 patients included in the efficacy analysis, including 95 and 68 percent with a major pathological response and a pathological complete response, respectively (defined as ≤10 and 0 percent residual viable tumor). No patients had disease recurrence during a median follow-up of 26 months.
"The high proportion of patients with a pathological response observed after only four weeks of treatment in our study, together with the safety profile, may provide sufficient justification to provide immunotherapy to patients with radiographically assessed high-risk disease, especially if three-year disease-free survival data from this study are positive," the authors write.
The study was funded by Bristol Myers Squibb, the manufacturer of nivolumab and ipilimumab.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.
Posted June 2024
Read this next
DDW: Systematic Program Increases Likelihood of Up-to-Date Colorectal Cancer Screening
FRIDAY, April 25, 2025 -- A systematic program of monitoring colorectal cancer (CRC) screening status increases up-to-date screening status, according to a study presented at the...
2000 to 2021 Saw Increase in Incidence of Pancreatic Adenocarcinoma
WEDNESDAY, April 23, 2025 -- From 2000 to 2021, there was an increase in the incidence of pancreatic adenocarcinoma, which was seen in all age groups, according to a study...
Breast, Colorectal Cancer Screening Higher Than Lung Cancer Screening
TUESDAY, April 15, 2025 -- Among individuals eligible for lung cancer screening (LCS), use of breast cancer screening (BCS) and colorectal cancer screening (CCS) is much higher...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.